Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

As of Friday, December 12, Lantheus Holdings, Inc.’s LNTH share price has surged by 5.44%, which has investors questioning if this is right time to sell.

Broadcom on Thursday said its AI revenue will double in the current quarter, but shares slumped as investors focused on ...

Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $768 from $767 and keeps an Equal Weight rating on the ...

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Immix Biopharma is advancing NXC-201, showing 95% complete/near-complete response rates and superior safety. Learn why IMMX ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

For Immediate Release Chicago, IL – December 9, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva ...